Navigation Links
Isis Reports Strong Financial Results and Highlights for Fiscal Year 2008
Date:2/25/2009

- Exceeds 2008 Projections for Net Operating Income and Year-End Cash

- Achieves 2008 Positive Pro Forma Net Operating Income and Net Income

- Conference Call Webcast Wednesday, February 25, 8:30 a.m. EST at www.isispharm.com

CARLSBAD, Calif., Feb. 25 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) today announced its 2008 financial results and business highlights. Isis exceeded its 2008 financial guidance by ending 2008 with positive pro forma net income of $3.1 million and positive pro forma net operating income of $226,000. The considerable improvement in Isis' financial results from 2007 was due to a significant increase in revenue that Isis generated in 2008 from its corporate partnerships. On a GAAP basis, Isis' loss from operations of $13.1 million and net loss of $12.0 million also improved significantly from its 2007 loss from operations and net loss. In addition to creating a continuing revenue base, Isis' corporate partnerships have considerably improved its cash position allowing Isis to finish 2008 with $491 million of cash, which does not include the $175 million that Isis received in January 2009 when it completed the sale of its Ibis Biosciences subsidiary to Abbott Molecular Inc (AMI).

"We believe that we are now at the beginning phase of sustained financial strength as evidenced by our 2008 financial results. With the sale of Ibis at the beginning of 2009, we started the year with more than $650 million in cash. In addition, we ended the year with positive pro forma net operating income and net income, further demonstrating our move toward continued financial strength. We expect to continue to benefit financially from the successful execution of our business strategy in 2009 and to move closer
'/>"/>

SOURCE Isis Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related medicine news :

1. Lehigh Valley-Based PPO, Valley Preferred, Reports Marked Improvement in Disease Management & Wellness Outcomes
2. Valeant Pharmaceuticals Reports Fourth Quarter and Full Year Financial Results
3. Symmetry Medical Reports Fourth Quarter and Full Year 2008 Financial Results
4. ev3 Inc. Reports 2008 Fourth Quarter and Full-Year Financial Results and 2009 Guidance
5. Update: Onyx Pharmaceuticals Reports Record Full Year and Fourth Quarter 2008 Financial Results
6. HealthSouth Reports Results for Fourth Quarter Ended December 31, 2008
7. Onyx Pharmaceuticals Reports Record Full Year and Fourth Quarter 2008 Financial Results
8. Solta Medical Reports Fourth Quarter and Full Year 2008 Results
9. 1 in 10 Ex-NFL Players Used Steroids, Poll Reports
10. ISTA Pharmaceuticals Reports Fourth Quarter and Full-Year 2008 Financial Results
11. Nyer Medical Group, Inc. Reports Revenues of $19.0 Million for the Quarter Ended December 31, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/3/2015)... Vancouver personal injury lawyers at Jiwa ... now handle personal injury claims resulting due to bus ... more and more people turn towards mass transportation for ... suffering, serious injury and also deaths. , “If ... accident in BC you may have an ICBC Claim,” ...
(Date:6/3/2015)... 03, 2015 VeoMed and Decker ... online and mobile access to premier Continuing Medical ... of Certification (MOC) activities. , ... courses to Decker’s extensive lists of physicians, residents, ... access to VeoMed’s premier online and live-streamed courses. ...
(Date:6/3/2015)... Plano, Texas (PRWEB) June 03, 2015 ... Intelligence and Analytics solutions, today announced the launch ... Studio EXtensions (DSX) for SAP® BusinessObjects™ Design Studio. ... embed additional visualization capabilities and advanced functionalities into ... of the DSX suite, Visual BI is adding ...
(Date:6/3/2015)... TN (PRWEB) June 03, 2015 According ... Inquisitr police officers intercepted fake oxycodone pills which ... pills were doctored to look legitimate, and even sported ... officers are warning those consuming 30 mg oxycodone to ... the pills online or buy them illegally on the ...
(Date:6/3/2015)... These are challenging and unpredictable times for traditional ... digital-first business are rewriting the rules for business as ... for traditional businesses to take on a more agile ... services. On top of this there is a ... to bring new innovation and approaches to business. , ...
Breaking Medicine News(10 mins):Health News:Jiwa Law Corporation Now Handles Personal Injury Claims Involving Bus Accidents 2Health News:VeoMed and Decker Intellectual Properties, the Owner of Scientific American Medicine, Announce a Partnership to Expand Access to Premier Online CME Courses 2Health News:Visual BI Launches Second Release for its Design Studio EXtensions (DSX) for SAP® BusinessObjects™ Design Studio 2Health News:Visual BI Launches Second Release for its Design Studio EXtensions (DSX) for SAP® BusinessObjects™ Design Studio 3Health News:Fake Oxycodone Pills of Fentanyl Discovered in Tennessee by Police 2Health News:Fake Oxycodone Pills of Fentanyl Discovered in Tennessee by Police 3Health News:Chief Digital Officer of Travelex joins Bayer, Abellio and Just Eat at The Open Mobile Summit London 2
... more predominant in women, the reasons for this are ... on the risk and severity of RA, but the ... data from the Womens Health Initiative (WHI) clinical trials ... significant differences in the risk of developing RA or ...
... in Australian Research During an Event ... 2 April, PHILADELPHIA and LONDON, Feb. 28 ... ; TSX: TOC) and leading provider,of information solutions to ... honor Australia,s preeminent,researchers at the National Press Club in ...
... TAMPA, Fla., Feb. 27 Sirion Therapeutics, ... that its New Drug Application (NDA) for ... and Drug Administration (FDA) and granted,priority review. ... FDA for,its investigational compound Durezol(TM) (difluprednate ophthalmic,emulsion) ...
... Screening breast cancers for three receptors could help doctors ... A study published in the open access journal Breast ... negative for estrogen receptor (ER), progesterone receptor (PR) and ... appear to be most at risk from developing brain ...
... Revenues Up 38.8%, Nine-Month Revenues Up 40.6%, ETHEX Revenue ... Months Ther-Rx Revenue Up ... ST. LOUIS, Feb. 27 KV Pharmaceutical Company,(NYSE: ... and first nine months of fiscal 2008 ended December ...
... CORAL SPRINGS, Fla., Feb. 27 Boca Pharmacal, ... Administration has granted,final approval for the Company,s Abbreviated ... of Pamlab,s Palgic(R) Oral Solution,(Carbinoxamine Maleate Oral Solution) ... immediately., Carbinoxamine Maleate Oral Solution 4mg/5mL is ...
Cached Medicine News:Health News:Hormone replacement therapy appears to have no effect on risk and severity of rheumatoid arthritis 2Health News:Thomson Scientific To Honor Australia's Top Researchers With Dedicated Australian Research Day 2Health News:Thomson Scientific To Honor Australia's Top Researchers With Dedicated Australian Research Day 3Health News:Sirion Therapeutics Receives NDA Acceptance and Priority Review From the FDA for Durezol(TM) in the Treatment of Postoperative Ocular Inflammation 2Health News:Breast cancer subtypes linked to survival from secondary brain tumors 2Health News:KV Pharmaceutical Reports Record Revenues for Fiscal 2008 Third Quarter and Year-to-Date on a Preliminary Basis 2Health News:KV Pharmaceutical Reports Record Revenues for Fiscal 2008 Third Quarter and Year-to-Date on a Preliminary Basis 3Health News:KV Pharmaceutical Reports Record Revenues for Fiscal 2008 Third Quarter and Year-to-Date on a Preliminary Basis 4Health News:KV Pharmaceutical Reports Record Revenues for Fiscal 2008 Third Quarter and Year-to-Date on a Preliminary Basis 5Health News:KV Pharmaceutical Reports Record Revenues for Fiscal 2008 Third Quarter and Year-to-Date on a Preliminary Basis 6Health News:KV Pharmaceutical Reports Record Revenues for Fiscal 2008 Third Quarter and Year-to-Date on a Preliminary Basis 7Health News:KV Pharmaceutical Reports Record Revenues for Fiscal 2008 Third Quarter and Year-to-Date on a Preliminary Basis 8Health News:KV Pharmaceutical Reports Record Revenues for Fiscal 2008 Third Quarter and Year-to-Date on a Preliminary Basis 9Health News:KV Pharmaceutical Reports Record Revenues for Fiscal 2008 Third Quarter and Year-to-Date on a Preliminary Basis 10Health News:KV Pharmaceutical Reports Record Revenues for Fiscal 2008 Third Quarter and Year-to-Date on a Preliminary Basis 11
(Date:6/3/2015)... AVT, Inc. (OTC Markets: AVTC) ( www.autoretail.com ... today that their customer, Pharmabox, has introduced the world,s ... carries over 140 top selling brand name items typically ... Rite Aid-type store. As published in ... Miami -based Pharmabox worked with AVT to develop ...
(Date:6/3/2015)... , June 3, 2015  Flow cytometry ... around the globe and keeping track of wide-ranging ... competitive market. In particular, ensuring user-friendliness, fluorescence capabilities, ... are the most important factors influencing end-user purchase ... base. New analysis from Frost & ...
(Date:6/3/2015)... June 3, 2015 Varian Medical Systems (NYSE: ... selected to equip and service the new multi-room HollandPTC ... The company will book the equipment part of the ... HollandPTC is a key part of Medical Delta, the ... of Leiden, Delft and Rotterdam . ...
Breaking Medicine Technology:Pharmabox Introduces New Concept with a Boldly Designed Automated Retailing System 2Florescent Capabilities are the Primary Focus for Laboratories with Flow Cytometer Technologies 2Florescent Capabilities are the Primary Focus for Laboratories with Flow Cytometer Technologies 3Florescent Capabilities are the Primary Focus for Laboratories with Flow Cytometer Technologies 4Varian Medical Systems to Equip Proton Therapy Center in Netherlands 2Varian Medical Systems to Equip Proton Therapy Center in Netherlands 3
... Diagnostics Incorporated (NYSE: DGX ), the world,s leading ... Spark Acquisition Corporation, its wholly owned subsidiary ("Spark"), has extended ... shares of common stock of Celera Corporation (NASDAQ: ... p.m., New York City time, today, May 3, 2011, unless ...
... Calif., May 3, 2011 Alexza Pharmaceuticals, Inc. (Nasdaq: ... that it has entered into a definitive agreement with ... Life Sciences, to raise approximately $16.1 million in gross ... of common stock and warrants.  The Company agreed to ...
Cached Medicine Technology:Quest Diagnostics Announces One Day Extension of Offer to Acquire Celera to 5pm Today 2Quest Diagnostics Announces One Day Extension of Offer to Acquire Celera to 5pm Today 3Alexza Prices $16.1 Million Registered Direct Offering 2Alexza Prices $16.1 Million Registered Direct Offering 3Alexza Prices $16.1 Million Registered Direct Offering 4
... Cannulated Interference Screws. Optimal ... and graft selection options. ... without deformation, and chamfered ... threaded atraumatic tissue fixation. ...
Cannulated Interference Screws...
... mm Mini-TrueView Arthroscopes,Based on the TrueView II ... fibre optic telescopes for small joint arthroscopy ... fully autoclavable and very durable thanks to ... the new telescope class means bright images, ...
Stryker Endoscopy offers a wide variety of small-joint arthroscopes that produce a brilliant high-resolution image without sacrificing Stryker's ultra-high tip durability....
Medicine Products: